New scan could reveal hidden lung inflammation
NCT ID NCT03492762
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a radioactive tracer called Cu-DOTA-ECL1i that binds to certain inflammatory cells in the lungs. Researchers will use PET scans to see how the tracer spreads in people with fibrotic lung disease, comparing it to CT scans and clinical status. The goal is to develop a better way to track inflammation and guide treatment. The study enrolls 110 participants, including healthy never-smokers and current smokers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cu-DOTA-ECL1i (a radioactive imaging tracer)
- What this could lead to
- If successful, this imaging method could help doctors see inflammation in the lungs more clearly, leading to better diagnosis and personalized treatment for fibrotic lung diseases.
- What could go wrong
- This is a very early (Phase 1) study focused on imaging, not treatment. It may not lead to direct patient benefits, and the tracer's effectiveness in different lung conditions is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2018
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1/2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month. * Screening FEV1 and FVC \> 80% of predicted * Capable of lying still and supine within the PET/CT and PET/MR scanner for \~1 hour and follow instructions for breathing protocol during the CT portion * No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year * No known history of cardiac, pulmonary, hepatic or renal disease or diabetes * No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions * Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol * BMI ≤ 35 Exclusion Criteria: * Currently enrolled in another study using an investigational drug * Pregnancy (confirmed by urine pregnancy test) * Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes * Currently taking any prescription medications * Presence of an implanted device that is incompatible with CT or MRI scanning * Creatinine \> 1.30 mg/dL, AST \> 50 Units/L, ALT \> 55 Units/L, or total bilirubin \> 1.2 mg/dL
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Interstitial lung disease fibrotic lung disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.